Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11591856.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HIV-associated distal sensory polyneuropathy (DSP) is a common complication of AIDS. No effective treatment is available. The authors investigated the long-term effect (48 weeks) of the neurotrophin nerve growth factor (NGF) in an open-label study of 200 subjects with HIV-associated DSP. Similar to their previously reported double-blind study, the authors showed that NGF was safe and well tolerated and significantly improved pain symptoms. However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density.
Medical subject headings
- Acquired Immunodeficiency Syndrome
- Nerve Growth Factor
- Peripheral Nervous System Diseases